Excellence in Research and Innovation for Humanity

ICTAD 2018 : 20th International Conference on Thrombophilic and Antiphospholipid Disorders

Cape Town, South Africa
November 15 - 16, 2018

Conference Information

ICTAD Home Aims and Objectives Important Dates Call for Papers Committee Conference Program Conference Proceedings Conference Abstracts

Paper Submission

Paper Submission Paper Submission GUIDE

Conference Registration

Author RegistrationListener Registration Payment Registration Fees Sponsorship and Exhibition Volunteer Author Information Presentation Upload Conference Photos

Conference Publicity

Conference Flyer General ProgramEventsKeynotes

Conference Venue

Cape Town Lodge Hotel
101 Buitengracht Street
Cape Town, 8001, South Africa 
Tel: +27 21 422 0030
Fax: +27 21 422 0090
For direction to the venue you can use google maps.

ICTAD 2018 : 20th International Conference on Thrombophilic and Antiphospholipid Disorders


Medical and Health Sciences
South Africa
Cape Town
Abstracts/Full-Text Paper Submission Deadline   2017-12-15 00:00:00
Notification of Acceptance   2017-12-25 00:00:00
Final Paper (Camera Ready) Submission &
Early Bird Registration Deadline
  2018-10-15 00:00:00
Conference Dates   Nov 15-16, 2018
The ICTAD 2018: 20th International Conference on Thrombophilic and Antiphospholipid Disorders aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Thrombophilic and Antiphospholipid Disorders. It also provides the premier interdisciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the field of Thrombophilic and Antiphospholipid Disorders.
Antiphospholipid Antibodies, Antiphospholipid Syndrome (APS), and Obstetric APS for Patients
Antiphospholipid Syndrome Treatment Trends (Ongoing and Planned Interventional Studies with New Generation Oral Anticoagulants, B-cell inhibition, Complement Inhibition, Hydroxychloroquine, Statins, Peptide Therapy, and others)
Association with Antiphospholipid Syndrome and Other Systemic Autoimmune Diseases (Systemic Lupus Erythematosis, Rheumatoid Arthritis)
Clinical and Prognostic Significance of “Criteria” and “Non-criteria” Antiphospholipid Antibody Tests
Current Treatment strategies for Non-obstetric Antiphospholipid Syndrome
Current Treatment strategies for Obstetric Antiphospholipid Syndrome
Definition, Epidemiology, and Natural History of Antiphospholipid Syndrome
Disease Measurement Criteria in Antiphospholipid Syndrome
Genetics of Antiphospholipid Antibodies/Syndrome
Impact of Antiphospholipid Syndrome in General Population with Thrombosis and Pregnancy Morbidity
Impact of Pediatric APS in Children with Thrombosis
Mechanism(s) of Antiphospholipid Antibody-mediated Pregnancy Morbidity
Mechanism(s) of Antiphospholipid Antibody-mediated Thrombosis
Microangiopathic and Catastrophic Antiphospholipid Syndrome
Most Recent Strategies in the Treatment of Thrombosis in General Population
Origin of Antiphospholipid Antibodies
Strengths and Limitations of the Current Classification Criteria
Target Cells and Receptors that Interact with Antiphospholipid Antibodies
Thrombophilic and Antiphospholipid Disorders
International Science Index
Thrombophilic, Antiphospholipid Disorders
Thrombophilia, Antiphospholipid Disorders,Thrombosis,Systemic Lupus Erythematosis, Rheumatoid Arthritis,Oral Anticoagulants, B-cell inhibition, Complement Inhibition, Hydroxychloroquine, Statins, Peptide Therapy
International Medical and Health Sciences Committee